Expertise in
16
conditions

Dr. William R. Lumry

Allergy and Immunology
10100 N Central Expy, Suite 100, 
Dallas, TX 
Expertise in
16
conditions
10100 N Central Expy, Suite 100, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Lumry is an Allergy and Immunologist in Dallas, Texas. Dr. Lumry is highly rated in 16 conditions, according to our data. His top areas of expertise are Hereditary Angioedema, Angioedema, Hives, and Primary Immunodeficiency (PID).

His clinical research consists of co-authoring 118 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Licenses
Specialist in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

10100 N Central Expy, Suite 100, Dallas, TX 75231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Biological
Study Phase: Phase 4
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Biological
Study Phase: Phase 3
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: December 09, 2022
Intervention Type: Biological
Study Phase: Phase 3
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
View 6 Less Clinical Trials

118 Total Publications

Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.
Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema.
Journal: Allergy and asthma proceedings
Published: May 17, 2025
Similar Doctors
Richard Wasserman
Expertise in
7
conditions
Dr. Richard Wasserman
Allergy and Immunology | Pediatrics
Expertise in
7
conditions
Dr. Richard Wasserman
Allergy and Immunology | Pediatrics

Allergy Partners Of North Texas - Dallas

7777 Forest Lane, 
Dallas, TX 
 (2.0 miles away)
972-566-7788
Languages Spoken:
English
See accepted insurances

Richard Wasserman is a Pediatrics specialist and an Allergy and Immunologist in Dallas, Texas. Dr. Wasserman is highly rated in 7 conditions, according to our data. His top areas of expertise are Primary Immunodeficiency (PID), X-Linked Agammaglobulinemia, Common Variable Immune Deficiency, and Food Allergy.

Expertise in
28
conditions
Dr. David A. Khan
Allergy and Immunology
Expertise in
28
conditions
Dr. David A. Khan
Allergy and Immunology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (6.5 miles away)
817-987-3955
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Khan is an Allergy and Immunologist in Dallas, Texas. Dr. Khan is highly rated in 28 conditions, according to our data. His top areas of expertise are Hives, Anaphylaxis, Serum Sickness, and Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss Syndrome).

Expertise in
15
conditions
Dr. Richard F. Herrscher
Allergy and Immunology
Expertise in
15
conditions
Dr. Richard F. Herrscher
Allergy and Immunology

Allergy Immunology And Respiratory Care PA

8440 Walnut Hill Ln, 
Dallas, TX 
 (0.6 miles away)
214-207-0855
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Richard Herrscher is an Allergy and Immunologist in Dallas, Texas. Dr. Herrscher is highly rated in 15 conditions, according to our data. His top areas of expertise are Mast Cell Activation Syndrome (MCAS), Primary Immunodeficiency (PID), Sinusitis, and Allergic Rhinitis. Dr. Herrscher is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lumry's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile